Rycarfa 20 mg Tablets for Dogs

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
27-02-2024

Aktiivinen ainesosa:

Carprofen

Saatavilla:

Krka d.d., Novo Mesto

ATC-koodi:

QM01AE91

INN (Kansainvälinen yleisnimi):

Carprofen

Lääkemuoto:

Tablet

Prescription tyyppi:

POM-V - Prescription Only Medicine – Veterinarian

Terapeuttinen ryhmä:

Dogs

Terapeuttinen alue:

Anti Inflammatory NSAID

Valtuutuksen tilan:

Authorized

Valtuutus päivämäärä:

2014-04-03

Valmisteyhteenveto

                                Issued: April 2014
AN. 00911/2012
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rycarfa 20 mg tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Carprofen
20.00 mg
EXCIPIENTS:
Ferric oxide red (E172)
0.61 mg
Ferric oxide black (E172)
0.38 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Round, dark brown, marbled tablets with visible darker spots, one-side
scored and
bevel-edged.
The tablet can be divided into equal parts.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculoskeletal disorders
and
degenerative joint disease. As a follow up to parenteral analgesia in
the management
of post-operative pain.
4.3
CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in dogs less than 4 months of age.
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastrointestinal ulceration or bleeding, or where there
is evidence of a
blood dyscrasia.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Issued: April 2014
AN. 00911/2012
Page 2 of 5
Refer to Sections 4.3 and 4.5.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should be instigated.
See section 4.8.
The tablets are flavoured. In order to avoid any accidental ingestion,
store tablets out
of reach of the animals.
Special precaut
                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia